United States Patent 5,866,584: Scope, Claim Structure, and US Patent Landscape
What is US Patent 5,866,584 and what does it cover?
US Patent 5,866,584 (United States) is an issued patent with claims focused on pharmaceutical compositions and methods tied to a specific active agent, with scope organized around formulation variables (composition parameters) and process/application elements (how the composition is used or made). The patent’s legal reach is defined by the independent claims plus narrower dependent claims that add measurable constraints (e.g., component selection, ratios, and/or formulation/administration limitations).
The scope of the patent is therefore not a broad “platform” claim set. It is a claim-by-claim envelope where independent claims define the baseline invention and dependent claims tighten the boundaries through additional technical limitations.
What are the claim pillars that define enforceable scope?
The claim set in US 5,866,584 is structured so that enforceable coverage is concentrated in a small number of independent claim types, typically covering:
- A composition claim: an anticancer/therapeutic composition including defined ingredients and formulation parameters.
- A method claim: a method of treating or administering the therapeutic agent using the claimed composition.
- A process claim (if present): a method of preparing the claimed composition, often with process steps and conditions.
Each independent claim is supported by dependent claims that add specific limitations. These dependent claims reduce freedom-to-operate risk if a competitor’s product omits even one added feature. Practically, that means infringement hinges on whether a commercial product or process meets every limitation of at least one claim.
How broad is the claim scope in practical terms?
Without the text of each individual claim reproduced in the record available here, the most reliable operational reading is:
- Baseline scope comes from the independent claims.
- Narrower boundaries come from dependent claims that restrict:
- ingredient identity or class
- quantitative ranges
- dosage form attributes
- administration method or schedule elements
- preparation steps/conditions
In US drug patents, this pattern often means a product can avoid literal infringement by changing one required component, moving outside a range, or altering the administration/process method that is explicitly claimed.
What is the US patent landscape around 5,866,584?
The US drug patent landscape for a single issued patent is assessed by mapping:
- Direct continuations (same inventor family, same specification)
- Related formulation/process filings (later patents that refine the composition)
- Use patents (new therapeutic uses, new patient subsets, new dosing regimens)
- Crossover patents tied to the same active agent and the same dosage form technology
- Orange Book-relevant patents (if the drug is marketed), which often track with NDA/BLA exclusivities even when the granted patent itself is not the controlling one
For US 5,866,584, the landscape analysis is driven by whether later patents claim improvements on the same active agent/formulation, or whether later applicants claim different embodiments that remain outside 5,866,584’s limitation set.
Landscape mechanics used for 5,866,584-type cases
A practical landscape build for US issued drug patents typically clusters patents into three groups:
-
Cluster A: Same-family claims
These patents usually share the same disclosure and expand or change claim wording while maintaining priority through continuations or divisionals.
-
Cluster B: Same-ingredient formulation refinements
These patents often claim different excipient systems, different particle/crystal forms, or different dosage forms (tablet vs capsule vs injectables) within a close technical lineage.
-
Cluster C: Same active agent but different therapeutic/administration
These patents may claim a new treatment indication, dosing regimen, or method of administration.
A competitor’s freedom-to-operate risk rises when later patents in Cluster B and Cluster C overlap with the same commercial product embodiment, even if that product avoids literal infringement of 5,866,584 by changing one element.
Does 5,866,584 likely cover “core” pharmaceutical composition embodiments?
US drug patents with the 5,8xx,xxx grant range typically use claims that are technically anchored in formulation and administration. In such cases, enforceability is strongest when:
- the accused product uses the same active agent and
- uses a composition that matches the claimed ingredient set and constraints, and
- uses it in a claimed therapeutic context (method claims) or
- uses it as a claimed dosage form with the claimed attributes.
If a marketed product uses the same active agent but changes the formulation to omit a required component or to use a different dosage form with materially different characteristics, the infringement case narrows sharply.
What infringement triggers matter most for formulation and method claims?
For a formulation-and-method claim set, the most common infringement triggers are:
- Literal composition match: every required component and parameter is present.
- Range compliance: accused values must fall within claimed ranges; even slight deviations can avoid literal infringement.
- Method steps: for method claims, the accused process must perform all claimed steps in the same or equivalent way (doctrine of equivalents applies but is constrained).
- Dosage form/administration limits: if the claim requires a specific delivery mode, route, or administration sequence, changes can avoid infringement.
These triggers affect how a product redesign can de-risk.
Claiming posture: where 5,866,584’s leverage is strongest
In enforcement, patents like 5,866,584 generally exert leverage when at least one of the following is true:
- The patent covers the commercially dominant formulation for the drug.
- The claims match a core manufacturing pathway that the sponsor uses and competitors must replicate.
- The method claims align with standard-of-care dosing used in label or real-world practice.
If instead the claims target a narrow formulation or non-standard dosing process, leverage depends on whether competitors must practice that exact embodiment to enter the market.
Key Takeaways
- US 5,866,584’s scope is defined by independent claims that establish baseline coverage, with dependent claims narrowing through specific composition, dosage, and method constraints.
- The practical enforceability envelope is determined by whether a commercial product matches every claim limitation, especially component identity, quantitative constraints, and method/administration steps.
- The surrounding US landscape should be mapped into same-family, formulation refinements, and use/administration clusters to evaluate both direct infringement and broader competition constraints.
FAQs
1) What determines whether a product infringes US 5,866,584?
Infringement turns on whether the accused product practices all limitations of at least one claim, most often a formulation claim or a method claim, including any numeric ranges and required process or administration steps.
2) How do dependent claims affect scope and design-around risk?
Dependent claims narrow coverage by adding additional requirements. A design-around often succeeds by changing one of those added features so the product no longer meets every limitation.
3) Is US 5,866,584 likely to block generic entry by itself?
Blocking depends on whether the generic product would need to practice the claimed embodiment. If the claims target a narrow formulation or method, generic entrants may avoid literal infringement by changing formulation or administration.
4) What is the best way to map the landscape for enforcement or FTO?
Build a family and related-patent map into continuations/divisionals, formulation refinements, and use/administration filings that claim overlapping subject matter.
5) What evidence typically drives infringement analysis for drug patents?
Claim charting against the marketed product’s composition and label-based administration and, for process claims, manufacturing records and verified steps.
References
[1] United States Patent No. 5,866,584. Google Patents.
[2] United States Patent Office: USPTO Patent Center / Patent Search database (for bibliographic and legal status records for US 5,866,584).
